The growing demand for immune checkpoint inhibitors is mainly driven by the rising incidence of lung cancer, the increasing prevalence of melanoma, and the expanding number of research studies related to immune checkpoint inhibitors, among other factors, throughout the forecast period from 2025 to 2032.
New York, USA, Feb. 18, 2025 (GLOBE NEWSWIRE) — Global Immune Checkpoint Inhibitors Market to Cross USD 100 Billion by 2032 | DelveInsight
The growing demand for immune checkpoint inhibitors is mainly driven by the rising incidence of lung cancer, the increasing prevalence of melanoma, and the expanding number of research studies related to immune checkpoint inhibitors, among other factors, throughout the forecast period from 2025 to 2032.
DelveInsight’s Immune Checkpoint Inhibitors Market Insights report provides the current and forecast market analysis, individual leading immune checkpoint inhibitors companies’ market shares, challenges, immune checkpoint inhibitors market drivers, barriers, trends, and key market immune checkpoint inhibitors companies in the market.
Key Takeaways from the Immune Checkpoint Inhibitors Market Report
- As per DelveInsight estimates, North America is anticipated to dominate the global immune checkpoint inhibitors market during the forecast period.
- In the type segment of the immune checkpoint inhibitors market, the PD-1 inhibitors category had a significant revenue share in 2024.
- Notable immune checkpoint inhibitors companies such as F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Co., AstraZeneca Plc., Merck & Co., Inc., Sanofi, Regeneron, GSK plc., EMD Serono, Jiangsu Hengrui Medicine, BeiGene Ltd, Junshi Biosciences, and several others, are currently operating in the immune checkpoint inhibitors market.
- In January 2025, the FDA approved an investigational new drug application for R-5780, a precision-engineered synthetic biology therapy designed to activate immune pathways and enhance strong anti-tumor T cell responses in patients with solid tumors.
- In December 2024, the FDA approved tislelizumab-jsgr (TEVIMBRA) in combination with chemotherapy as a first-line treatment for adults with unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma that expresses PD-L1.
- In December 2024, the FDA awarded fast-track designation to IMM-1-104 for treating patients with unresectable or metastatic NRAS-mutant melanoma who have either progressed on or cannot tolerate PD-1/PD-L1 immune checkpoint inhibitors.
- In December 2024, the FDA awarded fast-track designation to AdAPT-001 in combination with nivolumab (OPDIVO) or atezolizumab (TECENTRIQ) for patients with recurrent or resistant advanced or metastatic soft tissue sarcoma whose disease progresses after at least one prior treatment.
To read more about the latest highlights related to the immune checkpoint inhibitors market, get a snapshot of the key highlights entailed in the Global Immune Checkpoint Inhibitors Market Report
Immune Checkpoint Inhibitors Overview
Immune checkpoint inhibitors are a class of immunotherapy drugs designed to enhance the body’s immune system to recognize and attack cancer cells. They work by targeting specific proteins, known as immune checkpoints, that can suppress the immune response. Cancer cells often exploit these checkpoints, such as PD-1, PD-L1, and CTLA-4, to evade detection by the immune system. By inhibiting these checkpoints, the drugs essentially “release the brakes” on the immune system, allowing T cells and other immune cells to target and destroy cancer cells more effectively.
These inhibitors have shown significant promise in treating various types of cancer, including melanoma, non-small cell lung cancer, and renal cell carcinoma. While the success of immune checkpoint inhibitors has revolutionized cancer therapy, they are not without challenges. Not all patients respond to these treatments, and some may experience immune-related side effects due to an overactive immune system. Ongoing research aims to refine the use of immune checkpoint inhibitors, either as standalone treatments or in combination with other therapies, to improve efficacy and reduce adverse effects.
Immune Checkpoint Inhibitors Market Insights
In 2024, North America held the largest share of the immune checkpoint inhibitors market, driven by the increasing incidence of cancers like bladder cancer and lung cancer. The growth of this market is also attributed to the rising number of product approvals, an increased focus on R&D by leading manufacturers, and expanding government initiatives within the region.
The growing approval of immune checkpoint inhibitors by the FDA has further contributed to the heightened demand for these treatments, fueling the overall market expansion. For instance, FDA-approved therapies such as pembrolizumab (KEYTRUDA), ipilimumab (YERVOY), nivolumab (OPDIVO), and atezolizumab (TECENTRIQ) are being used to treat various cancers.
Given these factors, the immune checkpoint inhibitors market in North America is expected to experience significant growth throughout the forecast period from 2025 to 2032.
To know more about why North America is leading the market growth in the immune checkpoint inhibitors market, get a snapshot of the Immune Checkpoint Inhibitors Market Outlook
Immune Checkpoint Inhibitors Market Dynamics
The immune checkpoint inhibitors market has seen significant growth over the past decade, largely driven by advances in immuno-oncology therapies. ICIs work by blocking the regulatory pathways that tumors exploit to evade immune system detection, thus allowing the immune system to attack and destroy cancer cells. The market is currently dominated by key players such as Bristol-Myers Squibb (OPDIVO), Merck & Co. (KEYTRUDA), and Roche (TECENTRIQ), whose offerings target critical checkpoint proteins like PD-1, PD-L1, and CTLA-4. These inhibitors have shown efficacy across various cancers, including melanoma, lung cancer, and more recently, head and neck cancers.
As the market matures, the introduction of novel immune checkpoint inhibitors and combination therapies is reshaping the landscape. The increasing approval of ICIs for multiple indications is expanding their therapeutic use, leading to enhanced treatment regimens and personalized medicine approaches. The ability to combine checkpoint inhibitors with other therapies like targeted therapies, chemotherapy, and radiation is further boosting the potential of ICIs in treating cancer. These combination therapies are being heavily explored in clinical trials to improve response rates, overcome resistance mechanisms, and broaden the patient population eligible for treatment.
Despite the promising developments, the immune checkpoint inhibitors market faces several challenges that could affect its growth trajectory. One major obstacle is the high cost of these therapies, which limits their accessibility in many regions. Additionally, while ICIs have demonstrated effectiveness in a broad range of cancers, there are still concerns regarding their side effects and the development of resistance. The complexity of managing adverse events, such as immune-related adverse effects (irAEs), requires specialized clinical management, which can increase healthcare costs and impact patient quality of life.
Looking forward, the market is expected to expand due to ongoing clinical research and the development of next-generation ICIs. New players and biosimilars are entering the market, which will likely drive competition and potentially lower costs. Furthermore, breakthroughs in biomarkers to predict patient response and companion diagnostics will play a crucial role in optimizing treatment strategies. As precision medicine becomes more prevalent, the ICIs market is poised for continued innovation and growth, offering hope for more effective and personalized cancer therapies.
Get a sneak peek at the immune checkpoint inhibitors market dynamics @ Immune Checkpoint Inhibitors Market Dynamics Analysis
| Report Metrics | Details |
| Coverage | Global |
| Study Period | 2022–2032 |
| Immune Checkpoint Inhibitors Market CAGR | ~15% |
| Immune Checkpoint Inhibitors Market Size by 2032 | USD 107 Billion |
| Key Immune Checkpoint Inhibitors Companies | F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Co., AstraZeneca Plc., Merck & Co., Inc., Sanofi, Regeneron, GSK plc., EMD Serono, Jiangsu Hengrui Medicine, BeiGene Ltd, Junshi Biosciences, and others |
Immune Checkpoint Inhibitors Market Assessment
- Immune Checkpoint Inhibitors Market Segmentation
- Immune Checkpoint Inhibitors Market Segmentation By Type: PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4 Inhibitors, and LAG-3 Inhibitors
- Immune Checkpoint Inhibitors Market Segmentation By Applications: Non-Small Cell Lung Cancer, Melanoma, Renal Cell Carcinoma, Bladder Cancer, and Others
- Immune Checkpoint Inhibitors Market Segmentation By End-User: Hospitals and Clinics, Diagnostic Laboratories, and Others
- Immune Checkpoint Inhibitors Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World
- Porter’s Five Forces Analysis, Product Profiles, Case Studies, KOL’s Views, Analyst’s View
Which MedTech key players in the immune checkpoint inhibitors market are set to emerge as the trendsetter explore @ Immune Checkpoint Inhibitors Companies
Table of Contents
| 1 | Immune Checkpoint Inhibitors Market Report Introduction |
| 2 | Immune Checkpoint Inhibitors Market Executive Summary |
| 3 | Competitive Landscape |
| 4 | Regulatory Analysis |
| 5 | Immune Checkpoint Inhibitors Market Key Factors Analysis |
| 6 | Immune Checkpoint Inhibitors Market Porter’s Five Forces Analysis |
| 7 | Immune Checkpoint Inhibitors Market Layout |
| 8 | Immune Checkpoint Inhibitors Market Company and Product Profiles |
| 9 | KOL Views |
| 10 | Project Approach |
| 11 | About DelveInsight |
| 12 | Disclaimer & Contact Us |
Interested in knowing the immune checkpoint inhibitors market by 2032? Click to get a snapshot of the Immune Checkpoint Inhibitors Market Trends
Related Reports
Immune Checkpoint Inhibitors Competitive Landscape
Immune Checkpoint Inhibitors Competitive Landscape and Market Forecast – 2034 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key immune checkpoint inhibitors companies, including Regeneron Pharmaceuticals, GlaxoSmithKline, Roche, Boehringer Ingelheim, Xencor, Taiga Biotechnologies, Jiangsu Alphamab Biopharmaceuticals, Dr. Reddy’s Laboratories, NATCO Pharma, AstraZeneca, EMD Serono Research & Development Institute, Bristol-Myers Squibb, ImmuneSensor Therapeutics, ImmunityBio, SQZ Biotechnologies, Teon Therapeutics, ALX Oncology, Astellas Pharma, Seagen, Hoffmann-La Roche, NextCure, MiNK Therapeutics, Genmab, BioNTech SE, STORM Therapeutics, Suzhou Kintor Pharmaceutical, Sanofi, Coordination Pharmaceuticals, among others.
Checkpoint Inhibitors Competitive Landscape
Checkpoint Inhibitors Competitive Landscape – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key checkpoint inhibitors companies, including BeiGene, Apollomics, BCN Biosciences, Phio Pharmaceuticals, Atridia, Jiangsu HengRui Medicine, EMD Serono, Innovent Biologics, Agenus, Eucure Biopharma, PharmaEngine, Vernalis, Array BioPharma, Genentech, Boehringer Ingelheim, Sentinel Oncology, Sierra Oncology, IMPACT Therapeutics, among others.
PD-(L)1 Inhibitors Market
PD-(L)1 Inhibitors Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the inhibitors, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key PD-(L)1 inhibitor companies, including FibroGen, EQRx, CStone Pharmaceuticals, Pfizer, Novartis, Arcus Biosciences, Agenus, Tracon Pharmaceuticals, Shanghai Henlius Biotech, Incyte Corporation, among others.
PD-1 and PD-L1 Inhibitors Competitive Landscape
PD-1 and PD-L1 Inhibitors Competitive Landscape – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key PD-1 and PD-L1 inhibitors companies, including Merck, Laekna Therapeutics, Genentech, Tracon Pharmaceuticals, Celgene, MedImmune, Hangzhou Sumgen Biotech, Lepu Biopharma, Harbour BioMed, Curis, BeiGene, Apollomics, Agenus, Boehringer Ingelheim, Jounce Therapeutics, Seagen, Ascletis Pharma, Secarna Pharmaceuticals GmbH & Co. KG, Arbutus Biopharma, among others.
PD-1 Inhibitor Pipeline
PD-1 Inhibitor Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key PD-1 inhibitor companies, including Genmab, RemeGen, Alphamab, OxSonics therapeutics, Light Chain Bioscience, ImmuneOnco Biopharma, Alpine Immune Sciences, Shanghai Henlius Biotech, Ocean Biomedical, Akeso Biopharma, Lyvgen Biopharma, Prestige Biopharma, ONO Pharmaceutical, among others.
DelveInsight’s Pharma Competitive Intelligence Service: Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion.
Other Business Consulting Services
Healthcare Conference Coverage
Pipeline Assessment
Healthcare Licensing Services
Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
CONTACT: Contact Us Shruti Thakur [email protected] +14699457679 https://www.delveinsight.com/medical-devices
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. IndiaChron.com takes no editorial responsibility for the same.